How to Determine Product Classification for Overseas Medical Device Registration

How to Determine Product Classification for Overseas Medical Device Registration

When registering a medical device overseas, product classification is the core step that determines the registration pathway, technical documentation requirements, quality management system audit scope, local agent responsibilities, and post-market maintenance obligations. Companies should first confirm whether the product falls within the scope of medical device regulation in the target country, then classify the risk level based on intended use, mechanism of action, body contact site and duration, and whether it contains drugs or bioactive ingredients. Classification systems vary across countries and regions: China, the European Union, the United States, Japan, the Association of Southeast Asian Nations (ASEAN), and the Gulf Cooperation Council (GCC) each have their own classification rules. Companies need to prepare product descriptions, working principles, clinical evidence, risk management reports, technical documentation, and agent authorization letters, and assess whether existing NMPA registration certificates, CE certificates, FDA 510(k) or PMA submissions can be reused. Common risks include incorrect classification leading to mismatched registration pathways, technical documentation not meeting target country requirements, missing clinical trials or performance verification, local agents not meeting qualification requirements, lack of localized labeling and instructions, and incomplete post-market surveillance plans. Companies should establish a regulatory team or engage a professional consultancy early, compare target country classification databases, develop classification decision trees, build evidence chain archives, and ensure that core technical documents can be reused with simultaneous localization for multi-country registrations.

Applicable Scenarios and Core Issues

Product classification for overseas medical device registration applies to all companies planning to export products to GHWP member countries (including ASEAN, the Middle East, Latin America, Africa, etc.). The core question is: which class does the product fall into in the target country? Classification directly determines the registration pathway (premarket notification, premarket approval, simplified registration, etc.), technical documentation requirements (ISO 13485 system files, risk management reports, clinical evaluation reports, software validation documents, etc.), local agent or authorized representative qualifications, and post-market maintenance obligations (adverse event reporting, annual updates, change notifications, etc.).

Companies should note that the same product may be classified differently in different countries. For example, a disposable sterile syringe is Class II in China, Class IIa under EU MDR, Class II (requiring 510(k)) in the US, and Class B in India. Therefore, NMPA classification results cannot be directly copied; each country must be evaluated individually.

Registration Classification Logic

Step 1: Determine if the Product is a Medical Device in the Target Country

Confirm the intended medical use based on the target country's legal definition (e.g., EU MDR Article 2, US FD&C Act Section 201, Japan PAL Act Article 2). If the product also has cosmetic, health monitoring, or other functions, verify whether it is classified as a medical device.

Step 2: Determine the Risk Level

Common dimensions include: single-use vs. reusable, invasive vs. non-invasive, active vs. non-active, whether it contains drugs or animal-derived components, whether it is supplied sterile, whether it has a measuring function, and whether it is standalone software. For example, the EU classifies according to MDR Annex VIII; the US according to 21 CFR Part 862-892 and the FDA classification database; ASEAN according to the AMDD classification criteria; and the GCC according to GSO 1999:2019.

Step 3: Select the Registration Pathway

For example, US Class I (exempt/non-exempt), Class II (510(k)/De Novo/exempt), Class III (PMA); EU MDR Class IIa generally requires notified body review; China NMPA Class II requires provincial or national approval; most Southeast Asian countries use the ASEAN Common Submission Dossier Template (CSDT), and high-risk products require clinical trials or clinical evidence.

Step 4: Assess the Potential for Reusing Existing Documentation

Existing CE technical documents (DoC, risk management report, clinical evaluation report, performance test reports) can be converted to target country formats; FDA 510(k) summaries may be accepted in some countries (e.g., Canada via MDL recognition); ISO 13485 certificates and MDSAP audit reports can simplify multi-country system audits. However, local language labels, instructions, and local clinical data (e.g., required by China and Japan) must be localized.

Step 5: Confirm Local Agent and Authorized Representative

Most countries require overseas manufacturers to appoint a local registration agent (distributor or local agent). The agent must hold a valid business license and bear legal responsibilities for post-market communication, adverse event reporting, and recall coordination.

Step 6: Initiate Post-Market Maintenance Strategy

Registration certificates are typically valid for 5 years and require early renewal; product changes (design, materials, indications, manufacturing process) must be assessed to determine if they trigger new registration or variation applications; establish an adverse event monitoring system and annual reporting system.

Documentation and Evidence

• Product description and intended use statement (including working principle, composition, body contact site and duration, sterility status, etc.)
• Quality management system documents (ISO 13485 certificate, MDSAP audit report, or equivalent)
• Risk management report (per ISO 14971 or equivalent target country standard)
• Performance verification reports (biocompatibility per ISO 10993, electrical safety per IEC 60601, sterilization validation, packaging validation, etc.)
• Stability test reports (accelerated aging, real-time aging, and transport simulation)
• Clinical evaluation report or clinical trial data (may be required depending on classification)
• Label and instruction for use drafts (must comply with target country language and content requirements)
• Local agent authorization letter (notarized or sworn)
• Post-market surveillance plan and adverse event reporting procedures

Common Mistakes

• Using NMPA classification results directly for other countries, leading to incorrect registration pathways (e.g., a China Class II product may be Class I exempt in the EU, or a China Class III product may be Class B in ASEAN).
• Ignoring the impact of product changes on classification (e.g., changing materials from inert to active, adding a drug coating, or upgrading software to add diagnostic functions).
• Failing to prepare clinical evidence required by the target country (e.g., China, Japan, and Brazil require local clinical trial data, while relying solely on CE clinical evaluations).
• Local agent not meeting qualifications (e.g., agent lacks medical device business license or cannot fulfill adverse event reporting obligations).
• Labels and instructions not fully localized (e.g., missing symbols, language non-compliant, or lacking local manufacturer or agent information).
• Neglecting differences in technical document formats for multi-country registration (e.g., ASEAN CSDT format differs from EU STED format and requires conversion).
• Not planning for certificate renewal cycles, causing the certificate to expire and product imports to be suspended.

Company Preparation Checklist

• ☐ Identify target countries and regions (list all countries intending to register)
• ☐ Collect target country medical device classification regulations and databases (e.g., FDA classification database, EU Medical Devices Sector)
• ☐ Complete product classification decision tree (record per country)
• ☐ Assess current quality system and technical documentation coverage
• ☐ Determine whether additional testing is needed (biocompatibility, electrical safety, software validation, clinical data)
• ☐ Select and contract local agents (each country requires a separate agent; one group may cover multiple countries)
• ☐ Prepare local language labels and instructions (multiple languages if needed)
• ☐ Compile registration application dossier in target country format (e.g., CSDT, STED, eSTAR)
• ☐ Develop post-market surveillance plan and adverse event reporting process
• ☐ Set up certificate management calendar (renewal, change notifications, annual updates)

AIMEILI Perspective

Companies most often mistakenly assume that a high-risk product is high-risk globally, but in practice, each country interprets the same risk dimensions differently based on local clinical practice and regulatory tradition. For example, blood glucose test strips are Class IIb (medium-high risk) under EU MDR, Class II (medium risk) in China, and Class II (exempt or 510(k) required) in the US. Therefore, classification cannot be based on guesswork or general experience; official classification decision trees or local regulatory consultants must be consulted.

In the early stages of a project, companies should prioritize creating a target country classification matrix that includes each country's classification, registration pathway, required level of clinical evidence, local agent requirements, technical document format, language requirements, and renewal cycle. Then assess the reusability of existing documentation. We recommend starting classification determination and document preparation at least 12 months in advance, as approval cycles range from 6 to 36 months across different countries.

Which documents can be reused? ISO 14971 risk management reports, ISO 10993 biocompatibility tests, IEC 60601 electrical safety tests, software lifecycle documentation (IEC 62304), and stability reports (provided transport conditions are similar) are generally reusable globally, but attention must be paid to local standard differences (e.g., Japan requires JIS standard compatibility evidence). Clinical evaluation reports can be partially reused in most countries, but China, Japan, Brazil, and India often require local clinical trials unless ethnic differences can be demonstrated to be minimal. Items that must be localized include: labels, instructions, packaging, agent agreements, and post-market adverse event reporting channels.

The choice of local agent is critical. The agent is not just a mailing address but bears legal liability. If the agent changes or their qualifications expire, the registration certificate may become invalid. We recommend choosing a reputable local entity with experience in medical device registration and signing an agreement that includes change notification obligations.

For multi-country registration, to reduce duplicate compilation and deficiency risks, it is best to use a set of core technical documents and then add country-specific sections. Establish document version control and ensure that the documents submitted for each country match the final product. Additionally, coordinate the renewal timelines of all certificates (e.g., CE certificate, ISO 13485 certificate, FDA registration number) to avoid cascading failures of all overseas registrations due to expiration of a primary certificate.

Frequently Asked Questions

What if the product has no corresponding classification in the target country?

This situation often occurs with emerging technologies (e.g., AI diagnostics, wearable health monitors). Companies should submit a classification determination request (e.g., FDA De Novo classification request, EU MDCG guidance document application) to the target country regulatory authority. Typically, a product description, comparison with existing products, risk management documentation, and clinical evidence are required. It is advisable to contact a recognized notified body or consultancy in that country for assistance. Sometimes analogy to similar products can be used, but with careful justification.

How can technical documents be unified when the same product is classified differently across countries?

Create a classification comparison table and a gap analysis report specifying additional requirements for each country. Develop a generic version of core technical documents (e.g., risk management report, test reports, clinical evaluation) and then add appendices, such as Appendix A: EU MDR Clinical Evaluation Supplement, Appendix B: China Local Clinical Trial Plan. This approach avoids rewriting entire documents each time while ensuring that regulators in each country see a complete evidence chain.

How to update classification and registration if the product changes during the registration process?

This depends on whether the change is significant. Definitions of significant change vary by country: EU MDR requires a variation application if changes in design, intended use, raw materials, or manufacturing process may affect safety or performance; US FDA requires a new 510(k) for any change that significantly affects performance or intended use; China NMPA requires registration change approval or filing. Companies must assess the classification impact before making changes and, if necessary, suspend exports until the registration documents are updated. We strongly recommend establishing an internal change control process that clearly defines triggers for reclassification.